Eli Lilly's Q2 2026 Zepbound sales will be shaped primarily by sustained volume growth in the GLP-1 obesity segment, where the drug captured nearly 70% of new U.S. prescriptions amid expanded manufacturing capacity and international rollout. Q1 results showed Zepbound revenue at $4.16 billion, up 80% year-over-year, contributing to a company-wide beat that prompted raised full-year guidance to the $82–85 billion range. Pricing headwinds in the low- to mid-teens percent range continue to offset some gains, while competitive dynamics with Novo Nordisk's offerings and potential new oral therapies add uncertainty. Traders are focused on the August 5 earnings release for updated segment data, with market-implied odds reflecting expectations of continued momentum tempered by macroeconomic factors influencing healthcare spending.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоНОВОЕ
5 авг. 2026 г.
$4 млрд
93%
$4,5 млрд
75%
$5 млрд
27%
$5,5 млрд
13%
$6 млрд
6%
$1,362 Объем
$4 млрд
$160 Объем
93%
$4,5 млрд
$467 Объем
75%
$5 млрд
$375 Объем
27%
$5,5 млрд
$140 Объем
13%
$6 млрд
$220 Объем
6%
This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Eli Lilly's Q2 2026 Zepbound sales will be shaped primarily by sustained volume growth in the GLP-1 obesity segment, where the drug captured nearly 70% of new U.S. prescriptions amid expanded manufacturing capacity and international rollout. Q1 results showed Zepbound revenue at $4.16 billion, up 80% year-over-year, contributing to a company-wide beat that prompted raised full-year guidance to the $82–85 billion range. Pricing headwinds in the low- to mid-teens percent range continue to offset some gains, while competitive dynamics with Novo Nordisk's offerings and potential new oral therapies add uncertainty. Traders are focused on the August 5 earnings release for updated segment data, with market-implied odds reflecting expectations of continued momentum tempered by macroeconomic factors influencing healthcare spending.
This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Открытие рынка: Jul 27, 2026, 1:43 PM ET
Объем
$1,362Дата окончания
5 авг. 2026 г.Открытие рынка
Jul 27, 2026, 1:43 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Eli Lilly's Q2 2026 Zepbound sales will be shaped primarily by sustained volume growth in the GLP-1 obesity segment, where the drug captured nearly 70% of new U.S. prescriptions amid expanded manufacturing capacity and international rollout. Q1 results showed Zepbound revenue at $4.16 billion, up 80% year-over-year, contributing to a company-wide beat that prompted raised full-year guidance to the $82–85 billion range. Pricing headwinds in the low- to mid-teens percent range continue to offset some gains, while competitive dynamics with Novo Nordisk's offerings and potential new oral therapies add uncertainty. Traders are focused on the August 5 earnings release for updated segment data, with market-implied odds reflecting expectations of continued momentum tempered by macroeconomic factors influencing healthcare spending.
This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Объем
$1,362Дата окончания
5 авг. 2026 г.Открытие рынка
Jul 27, 2026, 1:43 PM ETResolver
0x65070BE91...Eli Lilly's Q2 2026 Zepbound sales will be shaped primarily by sustained volume growth in the GLP-1 obesity segment, where the drug captured nearly 70% of new U.S. prescriptions amid expanded manufacturing capacity and international rollout. Q1 results showed Zepbound revenue at $4.16 billion, up 80% year-over-year, contributing to a company-wide beat that prompted raised full-year guidance to the $82–85 billion range. Pricing headwinds in the low- to mid-teens percent range continue to offset some gains, while competitive dynamics with Novo Nordisk's offerings and potential new oral therapies add uncertainty. Traders are focused on the August 5 earnings release for updated segment data, with market-implied odds reflecting expectations of continued momentum tempered by macroeconomic factors influencing healthcare spending.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы